Arash Rezazadeh Kalebasty, MD, discusses the dose modification impact of the addition of darolutamide for patients with metastatic hormone sensitive prostate cancer.
Arash Rezazadeh Kalebasty, MD
Advertisement
Articles by Arash Rezazadeh Kalebasty, MD
Arash Rezazadeh Kalebasty, MD, a hematologist/oncologist and research program director, Urologic Oncology, Norton Cancer Institute, discusses the safety profile of cabazitaxel in the CARD trial, which randomized patients with metastatic castration-resistant prostate cancer to cabazitaxel or one of 2 antiandrogen receptor agents, abiraterone acetate or enzalutamide.
Advertisement
Latest Updated Articles
Discussing the Safety Profile of Cabazitaxel in mCRPCPublished: October 20th 2019 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
